Vertex Pharmaceuticals overview after recent share performance Vertex Pharmaceuticals (VRTX) has seen its share price under ...

Vertex Pharmaceuticals VRTX is scheduled to report its first-quarter 2026 results on May 4, after market close. The Zacks ...

The market expects Vertex Pharmaceuticals (VRTX) to deliver a year-over-year increase in earnings on higher revenues when it ...

We recently compiled a list of the Top 10 AI-Powered Biotech Stocks to Buy Right Now. Vertex Pharmaceuticals Incorporated is ...

Vertex Pharmaceuticals (NASDAQ: VRTX) and Mirum Pharmaceuticals (NASDAQ: MIRM) are two biotech stocks that share the same ...

Vertex Pharmaceuticals (VRTX) ended the recent trading session at $430.50, demonstrating a -1.06% change from the preceding day's closing price. The stock fell short of the S&P 500, which registered a ...

Vertex Pharmaceuticals remains the leader in cystic fibrosis but is now executing a tangible diversification into pain, renal ...

Vertex Pharmaceuticals (NASDAQ: VRTX) has significantly underperformed broader equities over the past 12 months, with its shares down 10% since March of 2025, compared to a 15% gain for the S&P 500.

Vertex Pharmaceuticals (NASDAQ:VRTX) is set to give its latest quarterly earnings report on Thursday, 2026-02-12. Here's what investors need to know before the announcement. Analysts estimate that ...

"Mad Money" host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions ...

Deep-pocketed investors have adopted a bullish approach towards Vertex Pharmaceuticals (NASDAQ:VRTX), and it's something market players shouldn't ignore. Our tracking of public options records at ...